Skip to content

US · IPSC · BIOTECHNOLOGY

Century Therapeutics, Inc. (IPSC) intrinsic value and stock valuation

$1.17as of 2026-11-21 · Mkt cap 169.68M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Century Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values IPSC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IPSC’s statements →

Century Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Philadelphia, PA 19104 centurytx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$109.2M
20192025
Net income
-$-9.58M
20192025
Free cash flow
-$-104.72M
20192025
Total equity
$158.9M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$109.2M$6.59M$2.23M$5.2M$0.00
Operating income-$-15.04M-$-138.14M-$-146.55M-$-133.83M-$-94.88M
Net income-$-9.58M-$-126.57M-$-136.67M-$-130.93M-$-95.82M
EPSd-$-110.67K-$-1.61M-$-2.3M-$-2.27M-$-1.74M
Operating cash flow-$-103.88M-$-110.14M-$-88.35M$14.1M-$-89M
Capital expenditure-$-850K-$-150K-$-13.74M-$-30.6M-$-44.97M
Free cash flow-$-104.72M-$-110.29M-$-102.08M-$-16.55M-$-133.97M
Total assets$223.7M$353.2M$360.7M$486.5M$437.4M
Total debt$43.6M$53.8M$48.2M$49.4M$25.1M
Net debt-$-18.29M-$-4.61M$850K-$-34.85M-$-31.33M
Total equity$158.9M$161.4M$184.8M$302.7M$396.2M
Cash and short-term investments$117.1M$189.3M$172.7M$315.5M$222.9M
Income statement
20252024202320222021
Revenue$109.2M$6.59M$2.23M$5.2M$0.00
Cost of revenue$13.1M$0.00$0.00$0.00$4.58M
Gross profit$96.1M$6.59M$2.23M$5.2M-$-4.58M
Research and development expenses$95.7M$107.2M$92.7M$97.2M$75.7M
Selling, general and administrative expenses$24M$33.2M$34.7M$31.9M$14.7M
Other expenses-$-8.57M$4.33M$21.4M$10M$0.00
Operating expenses$111.1M$144.7M$148.8M$139M$90.3M
Cost and expenses$124.2M$144.7M$148.8M$139M$94.9M
Interest income$7.35M$13M$12.7M$2.99M$900K
Interest expense$0.00$0.00$540K$0.00$1.27M
Depreciation and amortization$13.1M$13.3M$13M$8.44M$4.58M
Ebitda$3.45M-$-111.47M-$-121.21M-$-121.2M-$-89.92M
Operating income-$-15.04M-$-138.14M-$-146.55M-$-133.83M-$-94.88M
Total other income/expenses, net$5.39M$13.4M$11.8M$2.99M-$-900K
Income before tax-$-9.65M-$-124.78M-$-134.79M-$-130.84M-$-95.78M
Income tax expense-$-70K$1.79M$1.88M$90K$40K
Net income-$-9.58M-$-126.57M-$-136.67M-$-130.93M-$-95.82M
Weighted average shares outstanding$86.6M$78.7M$59.3M$57.8M$55M
Weighted average diluted shares outstanding$86.6M$78.7M$59.3M$57.8M$55M
Balance sheet
20252024202320222021
Cash and short-term investments$117.1M$189.3M$172.7M$315.5M$222.9M
Net receivables$670K$1.52M$670K$780K$250K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$120.8M$194.1M$177M$319.7M$228.2M
Property, plant and equipment, net$66.2M$90.9M$92.1M$111.7M$69.8M
Goodwill and intangible assets$34.2M$34.2M$0.00$0.00$0.00
Long-term investments$2.36M$30.8M$91.1M$51.9M$135.9M
Total non-current assets$102.9M$159.2M$183.7M$166.8M$209.2M
Total assets$223.7M$353.2M$360.7M$486.5M$437.4M
Accounts payable$4.77M$3.08M$2.74M$5.45M$7.6M
Short-term debt$3.32M$4.87M$1.51M$6.98M$1.65M
Deferred revenue$0.00$109.2M$4.37M$7.15M$0.00
Total current liabilities$20.2M$129.8M$17.9M$29.8M$15.7M
Long-term debt$40.2M$49M$46.7M$42.4M$23.5M
Deferred revenue, non-current$0.00$0.00$111.4M$110.8M$0.00
Total non-current liabilities$44.5M$62.1M$158.1M$154M$25.5M
Capital lease obligations$43.6M$53.8M$46.7M$39.2M$15.2M
Total liabilities$64.8M$191.9M$175.9M$183.8M$41.1M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-791.92M-$-782.34M-$-655.77M-$-519.1M-$-388.17M
Accumulated other comprehensive income (loss)$30K$320K$110K-$-2.46M-$-650K
Total equity$158.9M$161.4M$184.8M$302.7M$396.2M
Total investments$57.6M$161.7M$216.5M$283.1M$302.4M
Total debt$43.6M$53.8M$48.2M$49.4M$25.1M
Net debt-$-18.29M-$-4.61M$850K-$-34.85M-$-31.33M
Cash flow statement
20252024202320222021
Net income-$-9.58M-$-126.57M-$-136.67M-$-130.93M-$-95.82M
Depreciation and amortization$13.1M$13.3M$13M$8.44M$3.75M
Stock-based compensation$6.84M$12.7M$14.6M$10.7M$4.66M
Change in working capital-$-114.55M-$-9.28M$9.38M$123.9M-$-2.8M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.56M-$-1.47M-$-2.36M-$-4.79M-$-1.85M
Net cash provided by operating activities-$-103.88M-$-110.14M-$-88.35M$14.1M-$-89M
Investments in property, plant and equipment-$-850K-$-150K-$-13.74M-$-30.6M-$-44.97M
Acquisitions, net$0.00-$-9.61M$0.00-$-238.22M$0.00
Net cash used for investing activities$107.5M$47.5M$61.1M-$-13.13M-$-298.34M
Common stock issued$170K$74.6M$520K$27.2M$221.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$170K$74.6M-$-9.72M$27.2M$417.8M
Net change in cash$3.8M$11.9M-$-36.94M$28.1M$30.4M
Cash at end of period$65M$61.2M$49.3M$86.2M$58.2M
Operating cash flow-$-103.88M-$-110.14M-$-88.35M$14.1M-$-89M
Capital expenditure-$-850K-$-150K-$-13.74M-$-30.6M-$-44.97M
Free cash flow-$-104.72M-$-110.29M-$-102.08M-$-16.55M-$-133.97M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Century Therapeutics, Inc.

        Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.

        CEO
        Brent Pfeiffenberger
        Employees
        78
        Beta
        1.56

        Explore

        Frequently asked questions

        What is the intrinsic value of Century Therapeutics, Inc. (IPSC)?

        InvestorsCraft does not currently publish an intrinsic value for IPSC. How the IC value is calculated.

        Is IPSC undervalued?

        InvestorsCraft does not publish an undervaluation signal for IPSC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.